uniQure (QURE) Stock Price, News & Analysis

Company Overview

uniQure N.V. is a biotechnology company focused on developing gene therapies intended to treat serious and potentially life-threatening diseases. The company uses adeno-associated virus (AAV) delivery technology to introduce genetic material into patients’ cells, with the goal of addressing the underlying causes of disease through a single administration.

uniQure’s lead commercial product, Hemgenix (etranacogene dezaparvovec), is a gene therapy for adults with hemophilia B who use factor IX replacement therapy. Hemgenix was developed by uniQure and is commercialized by CSL under a licensing and collaboration agreement. The company’s investigational pipeline has included gene therapies for Huntington’s disease, epilepsy and other severe conditions.

Founded in 1998 as Amsterdam Molecular Therapeutics, uniQure is headquartered in Lexington, Massachusetts, and maintains operations in the Netherlands. Its research, clinical development and commercial activities serve patients and healthcare markets in the United States, Europe and other international regions through internal programs and strategic partnerships.

Key Stats

• Today's Range: $21.37 to $23.15
• 50-Day Range: $23.37 to $51.05
• 52-Week Range: $8.73 to $71.50
• Volume: 1.58 million shs
• Average Volume: 2.46 million shs
• Market Capitalization: $1.59 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $53.73
• Consensus Rating: Moderate Buy

uniQure Stock Analysis - MarketRank™

uniQure scored higher than 53% of companies evaluated by MarketBeat, and ranked 448th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

uniQure has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 11 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

uniQure has a consensus price target of $53.73, representing about 136.2% upside from its current price of $22.74.

Amount of Analyst Coverage

uniQure has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for uniQure are expected to grow in the coming year, from ($3.82) to ($3.55) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of uniQure is -5.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of uniQure is -5.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

uniQure has a P/B Ratio of 7.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.00% of the float of uniQure has been sold short.

Short Interest Ratio / Days to Cover

uniQure has a short interest ratio ("days to cover") of 8.14.

Change versus previous month

Short interest in uniQure has recently increased by 0.47%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

uniQure does not currently pay a dividend.

Dividend Growth

uniQure does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.15

News Sentiment

uniQure has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 41 news articles for uniQure this week, compared to 10 articles on an average week.

Search Interest

Only 4 people have searched for QURE on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added uniQure to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, uniQure insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.65% of the stock of uniQure is held by insiders.

Percentage Held by Institutions

78.83% of the stock of uniQure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/29/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:QURE
• CIK: 1590560
• Web: www.uniqure.com
• Phone: (120) 240-6000
• Fax: 31-20-566-9272
• Employees: 221
• Year Founded: 1868

Price Target and Rating

• Average Price Target for uniQure: $53.73
• High Price Target: $80.00
• Low Price Target: $28.00
• Potential Upside/Downside: +135.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$198.97 million
• Net Margins: -1,350.73%
• Pretax Margin: -1,313.04%
• Return on Equity: -111.96%
• Return on Assets: -29.01%

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 10.01
• Quick Ratio: 10.01

Sales & Book Value

• Annual Sales: $16.10 million
• Price / Sales: 98.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.19 per share
• Price / Book: 7.16

Miscellaneous

• Outstanding Shares: 69,370,000
• Free Float: 66,140,000
• Market Cap: $1.59 billion
• Optionable: Optionable
• Beta: 1.06